Form 4: Tenax Therapeutics Chief Medical Officer Discloses Stock Option Grants and Trust Holdings

Tenax Therapeutics' Chief Medical Officer, Rich Stuart, reports stock option grants and holdings through irrevocable trusts.

Summary

• Rich Stuart, the Chief Medical Officer of Tenax Therapeutics, has disclosed his holdings of common stock and stock options.
• He holds 266 shares of common stock directly and 1194 shares indirectly through the Stuart Rich 2022 Irrevocable Trust.
• He also holds 1194 shares indirectly through the Andrea Rich 2021 Irrevocable Trust.
• Mr. Stuart has been granted stock options to purchase 500,000 shares at an exercise price of $5.94, vesting in four equal installments upon specific milestones related to a Phase 3 clinical trial and FDA approvals.
• Additional stock options include 2,848 shares vesting over four years starting June 9, 2023, 992 shares vesting over four years starting May 17, 2025, and 157 shares vesting on January 15, 2031.
• The reporting person disclaims beneficial ownership of the shares held in the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock options and holdings, which is generally positive for transparency. The vesting conditions tied to clinical milestones are also a positive sign.

Positives

• The vesting of a significant portion of the stock options is tied to the progress of a Phase 3 clinical trial and FDA approvals, aligning management's interests with the company's success.
• The disclosure provides transparency regarding the executive's holdings and potential future stake in the company.

Risks

• The vesting of the 500,000 stock options is contingent on the successful completion of a Phase 3 clinical trial and FDA approvals, which are subject to regulatory and clinical risks.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The vesting of a significant portion of the stock options is contingent on the successful completion of a Phase 3 clinical trial and FDA approvals.

Industry Context

This disclosure is typical for publicly traded companies and provides transparency regarding executive compensation and ownership. It is common for biotech companies to use stock options as incentives for management, especially tied to clinical trial milestones.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
• The vesting schedule tied to clinical trial milestones and FDA approvals is also a common practice in the biotech sector, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The use of irrevocable trusts for holding shares is a common estate planning strategy for executives, similar to what is seen with executives at companies like Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders gain insight into the executive's holdings and incentives.
• Employees may be indirectly impacted by the company's performance, which is tied to the vesting of the options.
• The vesting of options tied to clinical trial milestones and FDA approvals could impact the company's future valuation.

Key Dates

Keywords

stock options, insider trading, clinical trial, FDA approval, Tenax Therapeutics, executive compensation, beneficial ownership, irrevocable trust